Johnson & Johnson has completed the acquisition of Alios BioPharma, Inc., a privately held clinical-stage biopharmaceutical company focused on developing therapies for viral diseases, for a total purchase price of approximately $1.75 billion in cash.

With this acquisition complete, Alios BioPharma will become part of the infectious diseases therapeutic area of the Janssen Pharmaceutical Companies of Johnson & Johnson. The acquisition includes Alios BioPharma's portfolio of potential therapeutics for viral infections, including AL-8176, an orally administered antiviral therapy currently in Phase II studies for the treatment of infants with respiratory syncytial virus (RSV). The acquisition also includes two early-stage compounds for hepatitis C (HCV) that could potentially augment Janssen's existing HCV portfolio.

Source: Johnson & Johnson